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Effects of cardiomyopathy-linked mutations 
K15N and R21H in tropomyosin on thin-filament 
regulation and pointed-end dynamics
ABSTRACT Missense mutations K15N and R21H in striated muscle tropomyosin are linked to 
dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM), respectively. Tropo-
myosin, together with the troponin complex, regulates muscle contraction and, along with 
tropomodulin and leiomodin, controls the uniform thin-filament lengths crucial for normal 
sarcomere structure and function. We used Förster resonance energy transfer to study effects 
of the tropomyosin mutations on the structure and kinetics of the cardiac troponin core do-
main associated with the Ca2+-dependent regulation of cardiac thin filaments. We found that 
the K15N mutation desensitizes thin filaments to Ca2+ and slows the kinetics of structural 
changes in troponin induced by Ca2+ dissociation from troponin, while the R21H mutation has 
almost no effect on these parameters. Expression of the K15N mutant in cardiomyocytes 
decreases leiomodin’s thin-filament pointed-end assembly but does not affect tropomodu-
lin’s assembly at the pointed end. Our in vitro assays show that the R21H mutation causes a 
twofold decrease in tropomyosin’s affinity for F-actin and affects leiomodin’s function. We 
suggest that the K15N mutation causes DCM by altering Ca2+-dependent thin-filament regu-
lation and that one of the possible HCM-causing mechanisms by the R21H mutation is through 
alteration of leiomodin’s function.
INTRODUCTION
Many missense mutations in Tpm1.1, the predominant tropomyosin 
(Tpm) isoform in striated muscle, are linked to dilated cardiomyopa-
thy (DCM) and hypertrophic cardiomyopathy (HCM) (Redwood and 
Robinson, 2013). DCM is characterized by ventricular chamber dila-
tion and systolic dysfunction (Hershberger and Morales, 1993) and 
is the most common form of cardiomyopathy that leads to heart 
transplants in children and adults (Maron et al., 2006; Sweet et al., 
2015; Rusconi et al., 2017). HCM is the leading cause of sudden 
cardiac death in young people (Maron et al., 2009; Frey et al., 2011) 
and is defined by thickening of the ventricular walls with significant 
cellular disarray and myocardial scarring (Maron, 2002). Two Tpm1.1 
mutations, K15N and R21H, are identified in patients diagnosed 
with DCM and HCM, respectively (Hershberger et al., 2010; Fokst-
uen et al., 2011). Both mutations have been shown to alter the struc-
ture of Tpm1.1 near the N-terminus (Colpan et al., 2016b; Ly et al., 
2018). The K15N mutation reduces tropomyosin’s affinity for F-actin, 
tropomodulin (Tmod), and leiomodin (Lmod) (Colpan et al., 2016b, 
2017). Another important binding partner of Tpm1.1 in cardiac tis-
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obtain a clearer picture of how these mutations lead to disease by 
investigating their impact on Tpm1.1′s interaction with not only 
actin, Tmod, and Lmod but also cTn.
In cardiac muscle, actin-based thin filaments and myosin-based 
thick filaments form repeating contractile units called sarcomeres. 
Tpm1.1 stabilizes thin filaments by forming continuous polymers 
along the filament through head-to-tail association. Tpm1.1 is cru-
cial for cardiac muscle contraction (for reviews, see Geeves, 2012, 
and Gunning et al., 2015) where it interacts with cTn and regulates 
the interaction between actin and myosin. Muscle contraction is 
regulated both by intracellular Ca2+ levels and by the binding of 
myosin to actin, depicted by a model where thin filaments exist in 
equilibrium between three states (McKillop and Geeves, 1993; 
Pirani et al., 2005; Poole et al., 2006; Risi et al., 2017). cTn consists 
of three subunits: troponin C (cTnC), troponin I (cTnI), and troponin 
T (cTnT). In the absence of Ca2+, the hydrophobic pocket within the 
N-terminal domain of cTnC (N-cTnC) is closed, and both the inhibi-
tory region (cTnI-I, residues 130–149) and mobile domain (cTnI-M, 
residues 167–211) of cTnI bind strongly to actin. Ca2+ binding to the 
single regulatory site within N-cTnC increases the opening of the 
hydrophobic pocket within this domain, allowing N-cTnC to associ-
ate with the regulatory region of cTnI (cTnI-R, residues 150–165) and 
subsequently interact with cTnI-I and cTnI-M. These structural 
changes propagate through cTnT to Tpm1.1, causing Tpm1.1′s po-
sition on F-actin to change, exposing myosin-binding sites on actin’s 
surface, thereby enabling actomyosin interactions underlying mus-
cle contraction.
Thin filaments are polar with pointed ends, oriented toward the 
M-line, and barbed ends, attached to the Z-lines. Not only does 
Tpm1.1 stabilize and protect the thin filament from severing pro-
teins, it also recruits Tmod and Lmod, Tmod’s homologue, to the 
pointed end (Gregorio and Fowler, 1995; Tsukada et al., 2010; Ly 
et al., 2016) where they play crucial roles in regulating thin-filament 
assembly dynamics. Tmod1 and Lmod2 are the major isoforms 
found in cardiac tissues (Conley et al., 2001). Tmod1 is an efficient 
pointed-end capping protein (Weber et al., 1994, 1999), while 
Lmod2 does not completely prevent the filament to grow from the 
pointed end (Tsukada et al., 2010; Pappas et al., 2015). It is clear that 
both Tmod1 and Lmod2 are required for normal heart develop-
ment. Loss of Tmod1 resulted in failure of early myofibril formation 
and embryonic lethality (Fritz-Six et al., 2003), and knockout of 
Lmod2 led to shorter thin filaments, dilated cardiomyopathy, and 
lethality in juvenile mice (Pappas et al., 2015). According to a model 
suggested by Tsukada and coauthors, Tmod1 and Lmod2 work to-
gether in the presence of Tpm1.1 to maintain the uniform lengths of 
thin filaments that are critical for normal sarcomere architecture and 
function (Tsukada et al., 2010).
The K15N and R21H mutations are found within the first actin-
binding site of Tpm1.1 and are located in the position a and g of the 
coiled-coil heptad repeat, respectively (Parry and Squire, 1973; 
McLachlan and Stewart, 1976; Singh and Hitchcock-DeGregori, 
2007; Li et al., 2011). The mutations are located several amino acid 
residues apart from each other, but they are linked to different types 
of cardiomyopathies that cause opposite phenotypic responses of 
the heart. In general, in vitro functional assays demonstrate that 
DCM-causing mutations in thin-filament regulatory proteins de-
crease Ca2+ sensitivity of contractile function, whereas HCM-causing 
mutations tend to increase it (Hernandez et al., 2001; Robinson 
et al., 2002; Mirza et al., 2005, 2007).
To investigate whether the K15N and R21H mutations impose 
opposite effects on Ca2+-dependent cardiac thin-filament regula-
tion, we monitored structural and kinetic changes in cTn when thin 
filaments were under a free-Ca2+ or high-Ca2+ condition by means of 
Förster resonance energy transfer (FRET). We labeled residues 151 
or 167 of cTnI with 5-((((2-iodoacetyle)amino)ethyl)amino)naphtha-
lene-1-sulfonic acid (IAEDANS) as FRET donors and residue 89 
of cTnC with N-(4-dimethylamino-3,5-dinitrophenyl)maleimide 
(DDPM) as a FRET acceptor. We found that the K15N mutation in 
Tpm1.1 increases donor–acceptor separation distances, reduces 
Ca2+ sensitivity of reconstituted cardiac thin filaments, and de-
creases the rate of cTnI-R’s dissociation from N-cTnC triggered by 
the removal of Ca2+ from N-cTnC, while the R21H mutation has al-
most no effect on these parameters. Our in vitro assays show that 
the R21H mutation causes a twofold decrease in Tpm’s affinity for 
F-actin and affects Lmod2’s function. Visualization of filament bun-
dling by Lmod2 using transmission electron microscopy (TEM) sug-
gest that the R21H mutation in Tpm1.1 may alter the way Lmod2 
associates with the sides of F-actin. Expression of the K15N mutant 
in rat cardiomyocytes decreases Lmod2’s thin-filament pointed-end 
assembly but does not affect Tmod1’s assembly at the pointed end. 
We suggest that the K15N mutation cause DCM mainly by altering 
Ca2+-dependent thin-filament regulation. Data obtained for the 
R21H mutation shed light on possible mechanisms underlying de-
velopment of HCM, one of which involves the alteration of Lmod2’s 
function.
RESULTS
Effects of the K15N and R21H mutations in Tpm1.1 
on Ca2+-dependent cardiac thin-filament regulation
The R21H mutation in Tpm1.1 decreases Tpm’s affinity for 
F-actin by twofold. The major function of Tpm1.1 revolves around 
regulating muscle contraction, which is strongly dependent on 
Tpm1.1′s binding affinity for F-actin. One of the first steps in under-
standing the molecular consequences of a mutation in Tpm1.1 is to 
determine how the mutation affects its affinity for actin. We have 
previously determined that the K15N mutation leads to a threefold 
decrease in the affinity of Tpm1.1 for F-actin (Colpan et al., 2017).
Since residue Arg-21 is located next to residue Asp-20 in Tpm1.1, 
which is suggested to make direct contact with residues Arg-147, 
Lys-326, and Lys-328 in actin (Li et al., 2011), we speculated that the 
R21H mutation may alter Tpm1.1′s binding affinity for F-actin. To 
test this hypothesis, we conducted experiments where wild-type 
(WT) or mutated Tpm1.1 cosediments with F-actin (Figure 1). The 
amounts of actin and Tpm1.1 in the pellets, as well as those of 
Tpm1.1 in the supernatants, were quantified. The data were fitted 
to both the Hill model and the McGhee and von Hippel model, from 
which values of Kapp and Ko, respectively, were obtained. These 
binding constants representing Tpm1.1′s affinity for F-actin are sum-
marized in Table 1. Tpm1.1[R21H] displays a ∼twofold decrease in 
affinity for F-actin when compared with WT Tpm1.1.
Tpm1.1[K15N] decreases Ca2+ sensitivity of reconstituted cardiac 
thin filaments. In general, DCM-causing mutations in thin-filament 
regulatory proteins decrease Ca2+ sensitivity of contractile function, 
whereas HCM-causing mutations tend to increase it (Hernandez 
et al., 2001; Robinson et al., 2002; Mirza et al., 2005, 2007). In-
trigued by the question of whether the K15N and R21H mutations 
have opposite effects on Ca2+-dependent cardiac thin-filament reg-
ulation, we conducted FRET measurements monitoring structural 
changes within the regulatory head of the cTn core domain, consist-
ing of N-cTnC and cTnI-R, in the presence of Tpm1.1 (WT or mu-
tated). The probes for these measurements are IAEDANS, which is 
attached to either residue 151 or residue 167 in cTnI, and DDPM, 
which is attached to residue 89 in cTnC. These probes form two 
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separate FRET pairs, cTnI[S151CIAEDANS] – cTnC[S89CDDPM] and 
cTnI[S167CIAEDANS] – cTnC[S89CDDPM]. Using these probes, the in-
teraction between N-cTnC and cTnI-R was monitored to determine 
effects of the Tpm1.1 mutations on Ca2+-dependent thin-filament 
regulation.
In steady-state Ca2+ titration experiments, FRET permits the 
tracking of changes in cTnI-cTnC separation due to the addition of 
Ca2+. Binding of Ca2+ to N-cTnC leads to the association of cTnI-R 
with a hydrophobic patch within Ca2+-saturated N-cTnC, thereby 
removing cTnI-I from actin and enabling cTnI-I to interact with cTnC. 
Since residue 151 and residue 167 are located near the N-terminus 
and C-terminus of cTnI-R, respectively, their individual distances to 
residue 89, which is located within the central linker region of cTnC 
(close to N-TnC), are shortened as a result of these Ca2+-induced 
structural changes. As Ca2+ concentration increases, the monitored 
donor (IAEDANS) emission intensity decreases due to an increase in 
FRET efficiency.
FIGURE 1: The R21H mutation causes a twofold decrease in Tpm1.1′s affinity for F-actin. 
Binding of Tpm1.1 (WT or R21H) to F-actin was measured by cosedimentation. (A) Tpm1.1 
(0–3 μM) was combined with 5 μM F-actin and cosedimented at 20°C in 2 mM Tris–HCl, pH 8.0, 
25 mM imidazole, 100 mM KCl, 2 mM MgCl2, 1 mM EGTA, 0.2 mM CaCl2, 0.01% NaN3, 0.5 mM 
DTT, and 0.2 mM ATP. Pellets and supernatants were run on 10% polyacrylamide SDS gels and 
stained with Coomassie-blue. (B) Fraction maximal binding representing the stoichiometric 
binding of one Tpm1.1 per seven actin molecules was obtained from band density ratios of Tpm 
and actin in the pellet samples. Free-Tpm concentration in the supernatants was determined 
using a standard curve established at known Tpm concentrations. The data (n = 3) were fitted to 
the Hill equation to estimate the apparent binding constant (Kapp). (C) Analysis of Tpm’s affinity 
for F-actin using the McGhee–von Hippel model to estimate the association constant (Ko). The 
binding constants obtained from fitting the data to both models are reported in Table 1.
Hill model
McGhee and  
von Hippel model
Kapp (µM–1) Ko (µM–1)
WT 3.82 ± 0.30 0.061 ± 0.010
R21H 2.01 ± 0.22** 0.023 ± 0.021*
Each value is reported as mean ± SD. Asterisks indicate statistically significant 
differences from WT using one-way analysis of variance (ANOVA) with Holm-
Sidak post-hoc test (*p < 0.05 and **p < 0.01).
TABLE 1: Binding constants determined from Tpm1.1′s 
cosedimentation with F-actin by fitting the data (n = 3) to the Hill 
equation and the McGhee–von Hippel equation. 
Figure 2 demonstrates representative 
titration data in which the normalized FRET 
efficiency is plotted against pCa. Titration 
data were fitted to the Hill equation to 
obtain pCa50 values (Table 2). A pCa50 
value is an indicator of the thin filament’s 
Ca2+ sensitivity. Thin filaments carrying the 
cTnI[S151CIAEDANS]–cTnC[S89CDDPM] 
FRET pair have higher pCa50 values than 
those carrying the cTnI[S167CIAEDANS] – 
cTnC[S89CDDPM] FRET pair (Table 2), which 
is consistent with those reported in 
Schlecht et al. (2014). Under physiological 
conditions, muscle contraction is regulated 
by both Ca2+ and cross-bridge formation. 
Myosin S1 was added to the thin-filament 
complex prior to the titration. In the pres-
ence of myosin S1, pCa50 values increase 
(Table 2) due to an increase in N-cTnC’s af-
finity for Ca2+ as previously observed (Xing 
et al., 2009; Schlecht et al., 2014). It is well 
known that myosin crossbridges increase 
the affinity of cTnC for Ca2+ (Guth and 
Potter, 1987; Wang et al., 1999).
Values of pCa50 are used to com-
pare Ca2+ sensitivities between thin-fila-
ment samples containing WT Tpm1.1, 
Tpm1.1[K15N], or Tpm1.1[R21H]. Regard-
less of whether myosin S1 is present, 
Tpm1.1[K15N] appears to desensitize the 
thin filament to Ca2+. Tpm1.1[R21H] af-
fects only the myosin S1-bound thin filaments carrying the 
cTnI[S167CIAEDANS]–cTnC[S89CDDPM] FRET pair: they are more 
sensitive to Ca2+ in the presence of Tpm1.1[R21H] than in the 
presence of WT Tpm1.1 (Table 2).
Tpm1.1[K15N] increases the distance between cTnI-R and 
N-cTnC. To understand how the changes in Ca2+ sensitivity caused 
by Tpm1.1[K15N] correlate with structural changes within the cTn 
core domain, specifically changes in the distance between cTnI-R and 
N-cTnC, time-correlated single photon counting (TCSPC) fluores-
cence intensity decays of the donor were measured in the absence or 
presence of the acceptor. Figure 3A shows representative TCSPC 
fluorescence decays of the donor cTnI[S167CIAEDANS] in the presence 
of the acceptor cTnC[S89CDDPM]. By measuring the reduction in the 
characteristic decay time of the donor, which occurs as a function of 
the acceptor proximity, the interprobe distance distribution was de-
termined. Each interprobe distance distribution is represented by a 
Gaussian (Figure 3B), with characteristic parameters of mean inter-
probe distance r( ) and full width at half maximum (FWHM) of the 
distribution. The mean interprobe distance when thin filaments were 
under a free-Ca2+ condition and that when thin filaments were under 
a high, saturating Ca2+ condition were determined. These parame-
ters are summarized in Table 3. FWHM is directly related to the mobil-
ity of the donor relative to the acceptor and therefore provides a 
metric of interprobe flexibility (Robinson et al., 2004). A small FWHM 
value indicates a lack of interprobe mobility and structural flexibility, 
which occurs when cTnI-R binds to the hydrophobic pocket of Ca2+-
bound N-cTnC. The switching distance, denoted as rsw hereafter, 
which is the difference in the mean interprobe distance between the 
free- and high-Ca2+ conditions, is calculated for each thin-filament 
sample and displayed in Figure 3C.
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As reported in Table 3, the interprobe distances decrease on 
Ca2+ saturation, each of which is accompanied by a decrease in 
FWHM. In the presence of WT Tpm1.1, Ca2+ saturation results in an 
approximate 6.2-Å and 8.1-Å reduction in interprobe distance in thin 
filaments containing cTnI[S151CIAEDANS] and cTnI[S167CIAEDANS], 
respectively. This reduction in the interprobe distance is expected 
because cTnI-R comes in contact with N-cTnC on Ca2+ saturation. 
The decrease in FWHM value on Ca2+ saturation, again indicating 
reduced interprobe flexibility, was previously observed (Ouyang 
et al., 2010; Zhou et al., 2012). Values of FWHM slightly decrease 
when myosin S1 is present, analogously to previous observations 
(Ouyang et al., 2010; Schlecht et al., 2014).
While Tpm1.1[R21H] does not produce any effect on the inter-
probe distance under different biochemical conditions, thin fila-
ments carrying Tpm1.1[K15N] show noticeably greater mean inter-
probe distances than those seen in WT Tpm1.1-containing filaments 
FIGURE 2: The K15N mutation in Tpm1.1 decreases Ca2+ sensitivity of reconstituted cardiac 
thin filaments. Steady-state Ca2+ titrations of thin filaments carrying cTnI[S151CIAEDANS or 
S167CIAEDANS] and cTnC[S89CDDPM] in the absence (A, B) or presence (C, D) of myosin S1. Thin 
filaments were reconstituted in the presence of WT or mutated (K15N or R21H) Tpm1.1.
cTnIIAEDANS – Tpm1.1 
(n = 7–10) Thin filament
Thin filament + 
myosin S1
S151C – WT 6.79 ± 0.01 7.05 ± 0.01
S151C – K15N 6.68 ± 0.03*** 6.92 ± 0.02**
S151C – R21H 6.77 ± 0.03 7.03 ± 0.03
S167C – WT 6.54 ± 0.01 6.77 ± 0.01
S167C – K15N 6.28 ± 0.06*** 6.57 ± 0.04***
S167C – R21H 6.56 ± 0.02 6.83 ± 0.03*
Each value is reported as mean ± SD. Asterisks indicate statistically significant 
differences from WT using one-way ANOVA with Holm-Sidak post-hoc test 
(*p < 0.05, **p < 0.01, and ***p < 0.001).
TABLE 2: Parameter pCa50 obtained from steady-state Ca2+ titration 
measurements. 
(Table 3). This effect of Tpm1.1[K15N] on 
the interprobe distance is not altered on ad-
dition of myosin S1. As Tpm1.1[K15N] in-
creases the mean interprobe distance to a 
similar extent when filaments are under a 
free-Ca2+ condition or when they are under 
a high-Ca2+ condition, rsw is essentially the 
same as that observed in WT Tpm1.1-con-
taining thin filaments (Figure 3C).
Tpm1.1[K15N] decreases the rate of 
cTnI-R’s dissociation from N-cTnC follow-
ing the removal of Ca2+ from N-cTnC. We 
next examined the effect of both mutations 
in Tpm1.1 on the deactivation kinetics of 
thin filaments. Conformational changes in 
the core domain of cTn induced by the dis-
sociation of Ca2+ from N-cTnC were moni-
tored as a function of time using FRET 
stopped-flow measurements. In these 
measurements, thin filaments were first 
saturated with Ca2+. 1,2-bis(2-amino-
phenoxy)ethane-N,N,N′,N′-tetraacetic 
acid (BAPTA), a strong Ca2+-specific chela-
tor, was used to quickly remove Ca2+ from 
N-cTnC. FRET is used to measure the prog-
ress of the conformational transition as re-
constituted cardiac thin filaments switch 
from being under a high-Ca2+ condition to 
being under a free-Ca2+ condition. As one would expect, the emis-
sion intensity of the donor increases due to a decrease in FRET ef-
ficiency as cTnI-R moves away from N-cTnC. Figure 4 represents 
typical stopped-flow kinetic traces, where the rapid increase in the 
donor fluorescence is monitored. Rate constants associated with 
the dissociation of cTnI-R from N-cTnC due to the removal of Ca2+ 
from N-cTnC, referred to as IR-CN dissociation hereafter, are re-
ported in Table 4.
IR-CN dissociation rates of WT Tpm1.1-containing thin filaments 
are ∼34.0 s–1 and 43.7 s–1 for filaments with cTnI[S151CIAEDANS] 
and cTnI[S167CIAEDANS], respectively (Table 4). Faster IR-CN disso-
ciation associated with the donor located closer to cTnI-M, 
cTnI[S167CIAEDANS], was previously observed (Zhou et al., 2012). 
Addition of myosin S1 reduces the thin-filament deactivation kinet-
ics to different extents, which is also in agreement with previous 
studies (Zhou et al., 2012; Schlecht et al., 2014).
Thin filaments carrying Tpm1.1[K15N] show a decrease in the 
IR-CN dissociation rate, regardless of whether myosin S1 is present 
(Table 4). Tpm1.1[R21H]-containing thin filaments show no statisti-
cally significant change in IR-CN dissociation rate compared with WT 
Tpm1.1-containing thin filaments. Combining these results with 
those from the Ca2+ titration experiments, Tpm1.1[K15N] appears to 
reduce not only the sensitivity of thin filaments to Ca2+ but also their 
IR-CN dissociation kinetics, whereas Tpm1.1[R21H] has no effect on 
Ca2+-binding behavior or on IR-CN dissociation kinetics of thin 
filaments.
Tpm1.1[K15N] decreases the rate of ATP hydrolysis by myosin 
S1 when thin filaments are at saturating Ca2+ concentrations. 
Mutations in Tpm1.1 can alter the ability of actin to stimulate the 
ATPase activity of myosin (Mathur et al., 2011). In the presence of 
cTn, either the extent of inhibition at low Ca2+ levels or the extent of 
activation at saturating Ca2+ may be affected.
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FIGURE 3: The K15N mutation in Tpm1.1 increases the interprobe distances in reconstituted 
cardiac thin filaments. (A) Time-resolved fluorescence decay curves for thin filaments carrying 
cTnI[S167CIAEDANS] – cTnC[S89CDDPM] in the presence of myosin S1. Thin filaments were 
reconstituted with WT or mutated (K15N or R21H) Tpm1.1. Measurements were carried out 
when thin filaments were under a free-Ca2+ condition or under a high-Ca2+ condition. 
(B) Distance distributions were derived from fitting of the fluorescence decay curves in A using 
DecayFit. (C) Switching distances calculated from values displayed in Table 2. Averages and 
standard deviations are shown by columns and error bars (n = 3–4), respectively.
between very low and saturating Ca2+ 
(Supplemental Figure S1). At very low Ca2+ 
concentrations, there is not a statistically 
significant difference in ATPase rate deter-
mined for filaments containing WT and mu-
tated Tpm1.1. At saturating Ca2+ concentra-
tions, the ATPase rate measured for 
filaments containing Tpm1.1[K15N] is lower 
than that for WT Tpm1.1-containing fila-
ments. There is a small increase in the 
ATPase rate measured in the presence of 
Tpm1.1[R21H]. However, this difference 
does not reach a statistical significance rela-
tive to WT Tpm1.1.
Effects of the R21H mutation in 
Tpm1.1 on Tmod1 and Lmod2’s 
pointed-end capping abilities
Both Tmod1 and Lmod2 require Tpm1.1 to 
localize at the pointed end of the thin fila-
ment and their functions at the pointed end 
strongly depend on their binding to Tpm1.1 
(Weber et al., 1994; Gregorio and Fowler, 
1995; Chereau et al., 2008; Tsukada et al., 
2010; Ly et al., 2016). We have previously 
demonstrated that the K15N mutation af-
fects the pointed-end capping functions of 
both Tmod1 and Lmod2 (Colpan et al., 
2017). Here we examined effects of the 
R21H mutation in Tpm1.1 on Tmod1 and 
Lmod2’s capping activities.
We have recently demonstrated that the 
R21H mutation causes a ∼30-fold decrease 
in the binding affinity of αTM1a1-28Zip, a chimeric peptide contain-
ing 28 N-terminal residues of Tpm1.1 to Lmod2s1, an Lmod2 
fragment consisting of residues 2-41 (Ly et al., 2018). On the basis 
of this result, we speculated that the R21H mutation may exert a 
cTnI – Tpm1.1 (n = 3–4)
Free Ca2+ High Ca2+
r  (Å) FWHM (Å) r  (Å) FWHM (Å)
Thin filament
S151CIAEDANS – WT 41.1 ± 1.0 12.1 ± 1.2 34.9 ± 0.9 6.8 ± 0.6
S151CIAEDANS – K15N 43.1 ± 2.3* 13.7 ± 2.1 36.4 ± 2.1* 7.2 ± 1.5
S151CIAEDANS – R21H 41.0 ± 1.3 13.0 ± 0.9 34.5 ± 1.7 7.3 ± 2.6
S167CIAEDANS – WT 42.4 ± 1.7 14.2 ± 2.5 34.3 ± 1.1 7.0 ± 1.7
S167CIAEDANS – K15N 43.6 ± 2.0 14.3 ± 1.5 36.6 ± 2.1* 6.5 ± 0.9
S167CIAEDANS – R21H 41.2 ± 1.8 14.7 ± 2.9 33.5 ± 2.3 6.8 ± 2.0
Thin filament + myosin S1
S151CIAEDANS – WT 39.5 ± 1.7 10.5 ± 1.0 34.0 ± 2.5 6.2 ± 0.7
S151CIAEDANS – K15N 41.4 ± 1.0* 11.4 ± 0.7 35.8 ± 1.0 6.9 ± 1.3
S151CIAEDANS – R21H 40.2 ± 2.0 10.9 ± 2.0 34.3 ± 1.1 6.0 ± 2.4
S167CIAEDANS – WT 41.1 ± 1.5 11.1 ± 1.7 34.1 ± 0.7 6.8 ± 0.9
S167CIAEDANS – K15N 42.5 ± 1.3 12.0 ± 2.0 35.6 ± 1.5* 7.1 ± 1.2
S167CIAEDANS – R21H 41.3 ± 1.7 12.3 ± 1.9 34.8 ± 2.0 6.9 ± 1.2
Each value is reported as mean ± SD. Asterisks indicate statistically significant differences from WT using one-way ANOVA with Holm-Sidak post-hoc test (*p < 0.05).
TABLE 3: Interprobe distance distribution parameters. 
The ATPase rate of myosin S1 was measured in the presence of 
actin regulated by cTn and WT Tpm1.1, Tpm1.1[K15N], or 
Tpm1.1[R21H]. Wild-type Tpm1.1 and both mutants display 
excellent regulation with more than a 25-fold difference in rate 
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similar effect on the Tpm-dependent pointed-end capping ability 
of Lmod2. We questioned whether the mutation would change the 
ability of truncated Lmod2, Lmod21-514, to inhibit actin polymeriza-
tion at the pointed end. Lmod21-514 lacks the WH2 domain, which 
is the third actin-binding site in Lmod2, and caps Tpm1.1-saturated 
F-actin in a similar manner to Tmod1 (Tsukada et al., 2010). We 
performed a pyrene-actin polymerization assay to measure the rate 
of actin polymerization at the pointed end at saturating concentra-
tions of Tpm1.1 (WT or mutated) in the presence of Lmod21-514 
(Figure 5). While the rates of pointed-end polymerization in the 
presence of WT Tpm1.1 and Tpm1.1[R21H] are similar (Figure 5A), 
addition of Lmod21-514 noticeably decreases the actin polymeriza-
tion kinetics but to a greater extent for WT Tpm1.1-saturated fila-
ments than for Tpm1.1[R21H]-saturated filaments (Figure 5, B–D). 
Lmod21-514′s inhibition of pointed-end polymerization is much less 
effective in the presence of Tpm1.1[R21H] than in the presence of 
WT Tpm1.1.
We have previously determined that the R21H mutation in 
Tpm1.1 weakens the stability of complexes formed by αTM1a1-28Zip 
and a Tmod1 peptide containing a Tpm-binding site, Tmod1s1 or 
Tmod1s2 (Ly et al., 2018). However, the effect of the R21H mutation 
on αTM1a1-28Zip’s affinity for Tmod1s1 or Tmod1s2 could not be 
determined due to inability to calculate dissociation constants. We 
performed a pyrene-actin polymerization assay to test whether 
Tmod1’s pointed-end capping ability was affected in the presence of 
Tpm1.1[R21H]. We saw that Tpm1.1[R21H] does not alter inhibition 
of pointed-end polymerization by Tmod1 (Supplemental Figure S2).
Effects of the K15N and R21H mutations on Tmod1 and 
Lmod2’s thin-filament pointed-end assembly in rat neonatal 
cardiomyocytes
To test whether the K15N or R21H mutations affect Tmod1 and 
Lmod2’s pointed-end assembly in cardiac muscle cells, we ex-
pressed mCherry-tagged versions of the mutations in rat neonatal 
cardiomyocytes via adenovirus. Immunoblot analysis revealed that 
the expression level of each construct was similar and approximately 
three times more than endogenous Tpm (Supplemental Figure S3). 
Sarcomeric assembly of the Tpm1.1 mutants is not noticeably 
different from that of WT Tpm1.1 in cardiomyocytes (Figure 6A). Im-
munofluorescence staining revealed a significant decrease in the 
number of cells with thin-filament pointed-end assembly of Lmod2 
following expression of Tpm1.1[K15N] compared with WT Tpm1.1 
(Figure 6). Expression of Tpm1.1[R21H] did not significantly change 
the assembly of Lmod2 (Figure 6). Lmod2 expression levels are 
unchanged in cells expressing Tpm1.1 mutants (Supplemental 
Figure S4). We also did not detect a change in the pointed-end 
assembly of Tmod1 on expression of either mutant (Supplemental 
Figure S5).
Effects of the K15N and R21H mutations on Lmod2’s 
binding to the sides of F-actin
It has been shown that in sarcomeres Lmod2 displays distribution 
along the length of thin filaments (Skwarek-Maruszewska et al., 
2010; Tsukada et al., 2010). In vitro cosedimentation assays indicate 
that Lmod2 may interact with the sides of F-actin (Skwarek-Marusze-
wska et al., 2010; Szatmari et al., 2017).
In this study, we used TEM to visualize complexes of F-actin and 
Lmod2 in the presence or absence of WT Tpm1.1 (Figure 7). F-actin 
forms bundles in the presence of Lmod2, suggesting that Lmod2 
binds along the side of the filament. We presume that Lmod2, on 
binding to the side of a filament, interacts with adjacent actin fila-
ments through at least one other actin-binding site. In the absence 
(Figure 7B) or presence (Figure 7C) of Tpm1.1, Lmod2 packs actin 
filaments into sparse thin bundles where individual actin filaments 
run in parallel (Figure 7, B and C, inserts).
To confirm our observations of the TEM images, we used cen-
trifugation to separate individual actin filaments from F-actin bun-
dles seen in the TEM samples, presuming that bundles may sedi-
ment at low centrifugation speeds while individual filaments 
should sediment at higher speeds. After Lmod2 was added to F-
actin in the absence or presence of Tpm1.1, the samples were 
centrifuged at 4000 × g. At this speed, we expected bundles to be 
spun down while individual filaments should remain in the super-
natant. The supernatants were then centrifuged at 213,600 × g. 
The pellets formed at each centrifugation step were analyzed us-
ing SDS–PAGE. The total pelleted actin combined from both steps 
was similar across all samples. At 4000 × g, the amounts of pelleted 
actin in the presence of Lmod2 were higher than those in the ab-
sence of Lmod2 (Figure 8), hence it is clear that addition of Lmod2 
leads to formation of F-actin bundles. There is a slight but not 
statistically significant decrease in the amount of pelleted actin 
when Tpm1.1 is present.
FIGURE 4: The K15N mutation in Tpm1.1 reduces the deactivation 
kinetics of reconstituted cardiac thin filaments induced by dissociation 
of Ca2+ from N-cTnC. Stopped-flow kinetic measurements for thin 
filaments labeled with cTnI[S167CIAEDANS] – cTnC[S89CDDPM] in the 
presence of myosin S1. Thin filaments were reconstituted with WT or 
mutated (K15N or R21H) Tpm1.1. Raw data were fitted to an 
exponential decay function using a built-in program associated with 
the KinTek instrument.
cTnI – Tpm1.1 (n = 3–4) Thin filament
Thin filament + 
myosin S1
S151CIAEDANS – WT 31.0 ± 2.1 28.5 ± 3.4
S151CIAEDANS – K15N 29.2 ± 2.9 26.4 ± 1.2
S151CIAEDANS – R21H 30.6 ± 2.7 31.8 ± 1.8
S167CIAEDANS – WT 43.7 ± 1.1 34.9 ± 1.0
S167CIAEDANS – K15N 37.4 ± 1.2*** 27.8 ± 0.7**
S167CIAEDANS – R21H 43.9 ± 2.3 35.2 ± 2.1
Each value is reported as mean ± SD. Asterisks indicate statistically significant 
differences from WT using one-way ANOVA with Holm-Sidak post-hoc test 
(**p < 0.01 and ***p < 0.001).
TABLE 4: IR-CN dissociation rates (s–1) induced by Ca2+ dissociation 
from cTnC. 
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Next, we investigated whether the Tpm1.1 mutations affect 
Lmod2-induced bundle formation. At 4000 × g, we detected a 
higher amount of pelleted actin when Tpm1.1[R21H] was present 
than those in the presence or absence of WT Tpm1.1 (Figure 8), 
indicating that Tpm1.1[R21H] induces heavier bundles. In the 
FIGURE 5: The R21H mutation in Tpm1.1 decreases pointed-end-capping ability of Lmod21-514. 
Pointed-end polymerization of actin filaments saturated with Tpm1.1 (1.25 μM for WT or 2 μM 
for R21H) in the absence (A) or presence (B) of 10 nM Lmod21-514 was monitored. 
(C) Dependence of the pointed-end capping effect on Lmod21-514 concentration in the presence 
of Tpm1.1. Inhibition of pointed-end actin polymerization by Lmod21-514 was quantified as 
Rexp/Rcontrol values. Initial rates (R) were determined as the first derivatives at time 0 of 
polymerization curves after exponential fitting. (D) Inhibition of actin polymerization in the 
presence of 10 nM Lmod2. Asterisks demonstrate statistically significant differences between 
groups (**p < 0.01) using one-way ANOVA with Holm-Sidak post-hoc test. Standard deviations 
are indicated as error bars (n = 3–4).
FIGURE 6: Assembly of Lmod2 at the pointed end of the thin filament is reduced in cells 
expressing Tpm1.1[K15N]. (A) Representative images of rat neonatal cardiomyocytes expressing 
mCherry-tagged WT Tpm1.1, Tpm1.1[K15N], or Tpm1.1[R21H] stained with an antibody to 
Lmod2 (green) and an antibody to α-actinin (red). Scale bar = 3 μm. (B) Mean percentage of cells 
with thin-filament pointed-end assembly of Lmod2 ± SD (n = 3 cultures). A one-way ANOVA with 
Dunnett’s post-hoc test was used to compare each mutant to WT (***p < 0.001).
presence of Tpm1.1[K15N], the amount of 
pelleted actin at 4000 × g was reduced 
compared with when only Lmod2 was 
present.
We used TEM to visualize F-actin bun-
dles formed in the presence of Tpm1.1[R21H]. 
In the presence of Tpm1.1[R21H], Lmod2 
packs F-actin into dense bundles (Figure 
7D), where actin filaments demonstrate ar-
rangement different from that observed in 
the presence of WT Tpm1.1 (Figure 7D, 
insert). Formation of thicker and more 
densely packed bundles in the presence of 
Tpm1.1[R21H] is consistent with our cosedi-
mentation data (Figure 8) because thicker 
bundles should sediment more efficiently at 
4000 × g than thinner bundles. There was no 
difference in the Lmod2/actin ratio in pre-
cipitated filaments, and, therefore, the differ-
ence in the bundle formation suggests 
that the R21H mutation affects the mode of 
binding of Lmod2 along the side of Tpm-
saturated F-actin.
DISCUSSION
Effects of both mutations on the N-terminal 
structure of Tpm1.1 are characterized in 
previous studies (Colpan et al., 2016b; Ly 
et al., 2018). While both mutations decrease 
the α-helical content of Tpm1.1 near its N-
terminus, the R21H mutation results in a 
more pronounced structural effect: it causes 
a ∼60% reduction in the helical content of 
αTm1a1-28Zip, a chimeric peptide contain-
ing the first 28 residues of Tpm1.1 and sig-
nificantly decreases the peptide’s thermal stability (Ly et al., 2018). 
Residues Lys-15 and Arg-21 are located near the overlap region 
between Tpm1.1 molecules which spans ∼11–15 residues (Green-
field et al., 2006; Frye et al., 2010) and interacts with ∼39 residues 
within the N-terminal region of cTnT (Pearlstone and Smillie, 1977; 
Jin and Chong, 2010). This cTnT-Tpm over-
lap complex is physiologically important. 
Many cardiomyopathy-linked mutations in 
the N-terminus of cTnT that binds to the 
Tpm overlap have been identified (Palm 
et al., 2001; Hershberger et al., 2009). The 
C-terminus of cTnT interacts with the N-ter-
minal domain of cTnI and C-terminal globe 
of cTnC, integrating cTnT into the core do-
main of cTn (Takeda et al., 2003). Since both 
mutations alter the local N-terminal confor-
mation of Tpm1.1, the mutations may pro-
duce structural effects that spread through 
the cTnT-binding overlap region to cTn, 
altering normal structural arrangements 
within cTn.
FRET has been used to study structural 
changes within cTn in many studies, includ-
ing those involving IAEDANS and DDPM 
probes attached to residue 151 or 167 or 
cTnI and residue 89 of cTnC, respectively 
(Robinson et al., 2004; Ouyang et al., 2010; 
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Schlecht et al., 2014). In this study, time-resolved fluorescence de-
cay measurements show that the K15N mutation in Tpm1.1 
increases mean interprobe distances when thin filaments are under 
a free-Ca2+ condition or under a high-Ca2+ condition, while the R21H 
mutation does not affect these distances. These data suggest that 
the K15N mutation cause alteration of normal structural arrange-
ments within cTn core domain, specifically the relative positions of 
N-cTnC and cTnI-R. In addition to the cTnT-binding overlap region 
between Tpm1.1 molecules, the K15N mutation in Tpm1.1 may ex-
ert such structural effects on the cTn core domain through another 
site in Tpm1.1 that binds to ∼25-residue region near the beginning 
of the C-terminal domain of TnT (Jin and Chong, 2010). The orienta-
tion of cTnT on the thin filament is still under debate (Ohtsuki, 1979; 
Pirani et al., 2006; Paul et al., 2009, 2017; Yang et al., 2014). Al-
though it is clear that the N-terminus of cTnT extends from the core 
domain of cTn and makes contact with the Tpm overlap region, the 
structure of the N-terminus of cTnT with the Tpm overlap is not 
agreed on (Greenfield et al., 2006; Murakami et al., 2008; Frye et al., 
2010). It is possible that Lys-15 in Tpm1.1 is within the binding site 
to cTnT or affects binding to cTnT by disturbing the overlap region 
while Arg-21 is not. This would explain why more drastic structural 
changes in Tpm1.1 caused by the R21H mutation have very little 
effect on cTn.
Ca2+ titration experiments show that the K15N mutation in 
Tpm1.1 decreases the thin filament’s sensitivity to Ca2+, whereas the 
R21H mutation has almost no effect (Table 2). The effects of the 
K15N and R21H mutations in Tpm1.1 on the ATPase rates are in 
agreement with Ca2+ titration experiments. The K15N mutation 
therefore can join a growing list of DCM-linked mutations in thin-
filament regulatory proteins that reduce Ca2+ affinity of cardiac thin 
filaments (Mirza et al., 2005, 2007; Borovikov et al., 2009).
FIGURE 7: TEM images of negatively stained actin filaments in the absence (A) and presence 
(B–D) of Lmod2. F-actin (A) forms bundles in the presence of Lmod2 in the absence of Tpm1.1 
(B) or in the presence of WT Tpm1.1 (C) or Tpm1.1[R21H] (D). Inserts show different packing of 
actin filaments within Lmod2 induced bundles. Bar is 1 μm.
Decreased myofilament Ca2+ sensitivity 
has been identified as an important factor 
leading to DCM caused by thin-filament-
associated mutations, and early sensitiza-
tion of myofilaments to Ca2+ may be used 
as a therapeutic target to treat thin- 
filament-linked DCM (Du et al., 2007; Alves 
et al., 2017). In general, cardiomyopathy-
linked Tpm mutations can exert different 
effects on thin-filament regulation, and 
these effects could be carried along the 
thin filament through changes in Tpm’s po-
sition on actin, through cTn, and through 
alterations of actomyosin interactions 
(Redwood and Robinson, 2013). The effect 
of the K15N mutation on the core domain 
of cTn observed in this study could be car-
ried through cTnT, leading to alteration of 
cTn’s binding to actin. More specifically, 
cTn is known to bind to actin in the core 
domain at cTnI-I, cTnI-M and part of cTnT 
(Rieck and Dong, 2014). The reduction in 
Ca2+ sensitivity caused by the K15N muta-
tion may be explained by the observed 
increase in the mean interprobe distance, 
since the probability of cTnI-R interacting 
with the hydrophobic pocket of N-cTnC is 
reduced when they are farther apart. In 
addition to the decreased Ca2+ sensitivity, 
the K15N mutation results in a decrease in 
IR-CN dissociation rate triggered by the 
removal of Ca2+ from N-cTnC. As thin filaments switch from being 
under a high-Ca2+ condition to being under a free-Ca2+ condition, 
misalignment of cTnI-I and cTnI-M with respect to their target sites 
on actin could lead to a longer duration in which they randomly 
diffuse, after dissociating from cTnC, before binding to actin. 
Therefore, it is possible that the K15N mutation affects the struc-
ture of the core domain of cTn both by bringing cTnI-R out of its 
normal alignment with N-cTnC and by changing the normal orien-
tation of cTnI-I and cTnI-M with their respective binding sites on 
actin. These possible structural alterations within the cTn core do-
main are demonstrated as a schematic representation (Supple-
mental Figure S6), which is based on a previously proposed model 
for Tn activation and relaxation (Vinogradova et al., 2005). This 
would explain the increased mean interprobe distances when thin 
filaments are under a free-Ca2+ condition or under a high-Ca2+ 
condition, reduced Ca2+ sensitivity of thin filaments and decreased 
IR-CN dissociation kinetics as a consequence of the K15N mutation 
in Tpm1.1.
In this study, for the first time, the bundling of F-actin induced by 
side-binding Lmod2 is visualized using TEM. Formation of F-actin 
bundles in the presence of Lmod2 was confirmed using cosedimen-
tation (Figure 8). We also showed that the Tpm1.1 mutations have 
opposite effects on the degree of F-actin bundling. Using both 
cosedimentation and TEM, we demonstrated that the R21H 
mutation in Tpm1.1 induces thicker and more densely packed F-
actin bundles, which implies that the mutation changes how Lmod2 
associates with the sides of F-actin. Both mutations reduce Tpm1.1′s 
affinity for F-actin: we observe a twofold decrease for the R21H 
mutant and a threefold decrease for the K15N mutant (Colpan et al., 
2017). We suggest that changes in Tpm1.1′s affinity for F-actin 
caused by the mutations impose different effects on Tpm1.1′s 
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binding to F-actin and in turn alter Lmod2’s binding to the sides of 
F-actin.
We have previously demonstrated that the K15N mutation de-
creases the binding affinity of αTM1a1-21Zip, a chimeric peptide 
containing 21 N-terminal residues of Tpm1.1, for Tmod1s1, 
Tmod1s2, and Lmod2s1 peptides (Colpan et al., 2016b, 2017). As a 
result, the K15N mutation reduces the ability of Lmod21-514 and 
Tmod1 to inhibit pointed-end polymerization (Colpan et al., 2017). 
In this study, we detected a reduction in thin-filament pointed-end 
assembly of Lmod2 following expression of Tpm1.1[K15N] in rat 
neonatal cardiomyocytes (Figure 6), whereas the pointed-end as-
sembly of Tmod1 was found to be normal in these cells. It is possi-
ble that there is a connection between the reduced Lmod2-induced 
F-actin bundling in the presence of Tpm1.1[K15N] (Figure 8) and 
the decrease in Lmod2’s pointed-end assembly in cardiomyocytes. 
Future high-resolution structural studies showing how full-length 
Lmod2 interacts with F-actin will elucidate if there is such a 
connection.
Expression of mCherry-tagged Tpm1.1 constructs in rat neona-
tal cardiomyocytes allows for detection of the Tpm1.1 mutants in 
cardiomyocytes. Since the mCherry tag is located at the N-termi-
nus of Tpm1.1, which is close to the Tpm overlap region, the tag 
FIGURE 8: Separation of F-actin bundles induced by Lmod2 side binding using centrifugation. 
F-actin (4 μM) was mixed with saturating concentrations of Tpm1.1 (1.25 μM for WT or 2 μM for 
R21H) and 0.9 μM Lmod2 in 2 mM Tris–HCl, pH 8.0, 25 mM imidazole, 100 mM KCl, 2 mM 
MgCl2, 1 mM EGTA, 0.2 mM CaCl2, 0.01% NaN3, 0.5 mM DTT, and 0.5 mM ATP. (A) A 
representative image of the SDS–PAGE of pellets after centrifugation. (B) Fractions of pelleted 
actin were calculated by dividing band densities of actin pelleted at 4000 × g by those of the 
corresponding total pelleted actin. Averages and standard deviations of the data (n = 5–9) are 
demonstrated by columns and error bars, respectively. Asterisks demonstrate statistically 
significant differences between groups (*p < 0.05, ***p < 0.001) using one-way ANOVA with 
Holm-Sidak post-hoc test.
may interfere with Tpm1.1 function. How-
ever, it was shown that N-terminal tagged-
Tpm1.1 assembles along the length of the 
thin filament and is excluded from the Z-
disk, which mimics the assembly of endog-
enous Tpm (Helfman et al., 1999). Further-
more, cells expressing tagged-Tpm1.1 
have sarcomeres which shorten and appear 
to contract normally. These observations 
suggest the introduction of a fluorescent 
tag on Tpm1.1, as well as its overexpres-
sion, do not significantly compromise the 
function of Tpm1.1 or calcium-activated 
contraction.
Characterization of mutations in 
Tpm1.1 and other thin-filament regulatory 
proteins requires an understanding of the 
mutations’ effects not only on the struc-
ture and function of the affected protein 
but also on those of its binding partners. 
The data presented in this study and 
those from other studies that were dis-
cussed provide more insights into the 
disease-causing mechanisms by muta-
tions in Tpm1.1. We demonstrated that 
the Tpm1.1 mutations linked to different 
cardiomyopathies have different effects 
on the functions of Tpm1.1′s binding part-
ners. On the basis of our data, we suggest 
that the K15N mutation causes DCM 
mainly by altering the Ca2+-dependent 
thin-filament regulation. Data obtained 
for the R21H mutation shed light on pos-
sible mechanisms underlying develop-
ment of HCM. Knowing how cTn orients 
on the thin filament and the mode of 
binding of Lmod2 on the filament will sig-




Tpm1.1 (NP_001288265.1), cTnI (NP_058840.1), cTnC 
(NP_001029277.1), cTnT (NP_036808.1), Tmod1 (NP_990358.1), 
and Lmod2 (NP_001186644.2 for Lmod21-514, NP_444328.1 for full-
length Lmod2) sequences were obtained from the NCBI website.
Plasmid construction and site-directed mutagenesis
Recombinant full-length Tpm1.1 has an N-terminal extension con-
sisting of two residues Ala-Ser to mimic the native N-terminal acetyl 
group (Monteiro et al., 1994). The K15N and R21H mutations were 
individually introduced into full-length WT Tpm1.1 using site-di-
rected mutagenesis as previously described (Colpan et al., 2016b; 
Ly et al., 2018). To facilitate fluorophore labeling of cTnI and cTnC 
for FRET experiments in this study, single-cysteine mutants 
cTnI[S151C], cTnI[S167C], and cTnC[S89C] were generated through 
two steps of site-directed mutagenesis starting with plasmid tem-
plates encoding WT rat cTnI and cTnC as previously described (Xing 
et al., 2009; Zhou et al., 2012; Schlecht et al., 2014).
Full-length Lmod2 was cloned from cDNA generated from a 
neonatal mouse cardiomyocyte culture. A single alanine (GCA) 
was added to the C-terminus of Lmod2 (for efficient dithiothreitol 
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[DTT]-induced cleavage) and inserted into pTYB3 (New England Bio-
Labs, Ipswich, MA) between NcoI and SapI (blunted) restriction sites, 
which fuses an intein-tag to the C-terminus of Lmod2. The inserted 
sequence was confirmed by DNA sequencing, and the expression 
construct transformed into Escherichia coli BL21-Codon Plus (DE3)-
RIPL competent cells (Agilent Technologies, Santa Clara, CA).
Expression construct of rat Tpm1.1 was a gift from J. C. Per-
riard (Eidgenössische Technische Hochschule Zürich, Zürich, 
Switzerland). The sequence for Tpm1.1 was cloned into a modi-
fied pEGFP-C2 vector (Clontech, Moutain View, CA) in which 
GFP was replaced with mCherry. The K15N and R21H mutations 
were introduced to mCherry-tagged Tpm1.1 via site-directed 
mutagenesis using the following primer sequences: K15N (for-
ward: 5′-CTCGAC AAT GAGAACGCCTTGGATCGAGCAGAG and 
reverse: 5′-AGAA G ATGCAGATGCTGAAGCTCGACAATGAGA
ACG); R21H (forward: 5′-TTGGATCACGCAGAGCAGGCGGAG-
GCTGACAA and reverse: 5′-CTCTGCGTGATCCAAGGCGTT-
CTCTTTGTCGAG-) (Liu and Naismith, 2008). All sequences were 
confirmed by DNA sequencing.
Protein expression, purification, and labeling
Tpm1.1 (WT or mutants) was expressed in E. coli BL21 (DE3) and 
purified as previously described (Colpan et al., 2016a). G-actin was 
purified as described in Ly et al. (2016). G-actin was labeled with 
N-(1-pyrene)iodoacetamide as previously reported (Kouyama and 
Mihashi, 1981; Cooper et al., 1983) and stored in liquid nitrogen. 
Prior to pointed-end capping experiments, pyrene iodoacetamide-
labeled actin was thawed and centrifuged at 70,000 rpm (TLA-120.1 
rotor; Beckman Coulter, Brea, CA) and 4°C for 30 min to remove 
aggregates.
All recombinant cardiac troponin proteins were expressed and 
purified as previously described (Guo et al., 1994; She et al., 1998; 
Dong et al., 2001). Mutations introduced to WT cTnI and cTnC to 
create single cysteine mutants were found to have minimal effects 
on the functions of Tn (Dong et al., 1997b, 2001; Robinson et al., 
2004; Xing et al., 2009; Zhou et al., 2012). Each single cysteine 
cTnI mutant was modified with IAEDANS to be used as FRET do-
nor, and cTnC[S89C] was labeled with DDPM as FRET acceptor 
according to previously reported procedures (Robinson et al., 
2004). The labeling ratios were all greater than 95%, which was 
determined using spectroscopy with ε325 = 6000 cm–1M–1 for IAE-
DANS and ε442 = 2930 cm–1 M–1 for DDPM as in Schlecht et al. 
(2014). Myosin subfragment-1 (S1) was isolated by conducting chy-
motrypsin digestion of myosin purified from rabbit skeletal muscle 
(Xing and Cheung, 1994). Actin used in FRET experiments was pre-
pared from rabbit skeletal muscle and purified as in Ly et al. (2016).
Tmod1 was expressed and purified as previously described 
(Kostyukova et al., 2000). Lmod21-514 was purified according to 
Tsukada et al. (2010). Expression of Lmod2 was done with 0.4 mM 
IPTG in LB broth and shaking at room temperature for 4 h. Cells were 
collected by centrifugation (4000 × g, 15 min, 4°C). Pellets were re-
suspended in B-PER Bacterial Protein Extraction Reagent (Thermo 
Fisher Scientific, Waltham, MA) + DNase and Halt protease inhibitor 
cocktail (Thermo Fisher Scientific) and incubated for 15 min at room 
temperature followed by 15 min on ice. Column buffer (50 mM Tris–
HCl, pH 8.5, 500 mM NaCl, 1 mM EDTA, 0.2% Tween + protease 
inhibitor cocktail) was added, and the cells were sonicated on ice. 
Clarified extract (spun at 15,000 × g, 25 min, 4°C) was added to a 
column of chitin resin (New England BioLabs). Following washes with 
column buffer, self-cleavage was induced by overnight incubation in 
cleavage buffer (50 mM Tris–HCl, pH 8.5, 500 mM NaCl, 1 mM 
EDTA, 50 mM DTT) at 4°C. The cleavage resulted in tagless Lmod2 
with no extraneous sequence. Following elution, proteins were ex-
changed into 20 mM Tris–HCl, pH 8.0, 50 mM KCl, 2 mM MgCl2.
Recombinant human gelsolin was a gift from John Hartwig 
(Brigham and Women’s Hospital, Boston, MA). Protein purity was de-
termined using SDS–PAGE. Protein concentrations were determined 
by either using a BCA protein assay kit (Thermo Fisher Scientific) or 
measuring the difference between their absorptions at 294 nm at 
pH 7.0 and pH 12.5 in 6 M guanidine hydrochloride using difference 
extinction coefficients of 2357 cm–1 per 1 M tyrosine and 830 cm–1 
per 1 M tryptophan (Edelhoch, 1967; Fasman, 1989).
Cardiac thin-filament reconstitution
Actin, Tpm1.1 (WT or mutants), wild-type cTnT, labeled cTnI and 
cTnC were reconstituted into thin filaments using a cTn:Tpm1.1:actin 
molar ratio of 1:1.1:7 as previously described (Zhou et al., 2012; 
Schlecht et al., 2014). Briefly, following the stepwise dialysis to 
remove urea, salt concentration was gradually reduced from 
0.5 to 0.4, 0.3, 0.25, and 0.2 M KCl in the reconstitution buffer 
containing 30 mM 3-(N-morpholino)propanesulfonic acid (MOPS), 
pH 7.0, 5 mM MgCl2, 1 mM ethylene glycol-bis(2-aminoethylether)-
N,N,N′,N′-tetraacetic acid (EGTA), and 1 mM DTT. F-actin and 
Tpm1.1 (WT or mutants) were combined with the cTn complex at 
the dialysis step with 0.3 M KCl. After the dialysis step in 0.2 M KCl 
reconstitution buffer, thin filaments were dialyzed against the titra-
tion buffer containing 0.2 M KCl, 50 mM MOPS, pH 7.1, 5 mM 
nitrilotriacetic acid (NTA), 5 mM MgCl2, 2 mM EGTA, and 1 mM DTT 
for Ca2+ titration and fluorescence lifetime experiments. For 
stopped-flow experiments, the samples were dialyzed against a 
buffer containing 0.2 M KCl, 40 mM MOPS, pH 7.0, 5 mM MgCl2, 
10 µM EGTA, and 1 mM DTT. For all the experiments, myosin S1 
was dialyzed against the same buffer as the final buffer of the sam-
ples. Immediately before each experiment, 3 µM S1 and 5 mM ADP 
were added to 1 µM thin filaments. ADP-bound myosin is known to 
bind strongly to actin (Lymn and Taylor, 1970, 1971; Sweeney and 
Houdusse, 2010; Wulf et al., 2016). All Ca2+ titrations, lifetime, and 
stopped-flow experiments were conducted within 3–5 d following 
reconstitution to prevent sample degradation.
Steady-state Ca2+ titration fluorescence measurements
Measurements were carried out at 15 ± 0.1°C on an ISS PCI photon 
counting spectrofluorimeter equipped with a microtitrator. Prior to 
each measurement, appropriate buffer dilutions were made to re-
duce the KCl concentration to 0.15 M, while the rest of the buffer 
components remained the same (50 mM MOPS, pH 7.1, 5 mM NTA, 
5 mM MgCl2, 2 mM EGTA, and 1 mM DTT). The fluorescence inten-
sity of the donor (cTnI[S151CIAEDANS] or cTnI[S167CIAEDANS]) was 
monitored at 488 nm with excitation at 335 nm. In each titration, ali-
quots of 3 µl of 14 mM Ca2+ solution were successively injected into 
1.2 ml of the reconstituted thin-filament sample in the presence or 
absence of myosin S1. Adjusted fluorescence intensities were calcu-
lated from the experimental data to account for the effect of dilution 
on the fluorescence signal. The intensities were normalized and 
plotted against free-Ca2+ concentrations that were determined 
using an in-house program, with stability constants provided by 
Fabiato (1988). Titration data were fitted to the Hill equation as in 
Schlecht et al. (2014) to obtain pCa50, which is the midpoint of the 
titration or the half-maximal thin-filament activation, using Sigma-
Plot 12.5 (Systat Software, San Jose, CA):
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where I is the steady-state donor fluorescence intensity, Imax 
and Imin correspond to the donor intensity under Ca2+-free and 
Ca2+-saturated conditions, respectively, and nH is the Hill 
coefficient.
Time-resolved fluorescence measurements
TCSPC fluorescence decay of the donor (cTnI[S151CIAEDANS] or 
cTnI[S167CIAEDANS]) in the absence or presence of the acceptor 
(cTnC[S89CDDPM]) was monitored under the same buffer condi-
tions as used in Ca2+ titration experiments. Measurements were 
conducted on a FluoreCube time-correlated single-photon 
counting system (HORIBA Jobin Yvon, Edison, NJ) as previously 
described (Schlecht et al., 2014). Time-resolved fluorescence 
decays were fitted with multiexponential functions as previously 
discussed (Dong et al., 1997a; Schlecht et al., 2014) using the 
DecayFit 1.4 software. Fluorescence decay fitting yielded a distri-
bution of interprobe distances along with fitting parameters r , 
which is the mean interprobe distance or the distance corre-
sponding to the peak of the distribution, and the FWHM of the 
distribution.
Stopped-flow fluorescence measurements
Measurements were conducted at 6.0°C using a T-format KinTek 
stopped-flow spectrometer with a 1.8-ms dead time. Prior to 
each measurement, appropriate buffer dilutions were made to 
reduce the KCl concentration to 0.15 M, while the rest of the 
buffer components remained the same (40 mM MOPS, pH 7.0, 
5 mM MgCl2, 10 µM EGTA, and 1 mM DTT). In each measure-
ment, Ca2+-saturated reconstituted cardiac thin filaments were 
rapidly mixed with an equal volume of buffer containing an ex-
cess amount of BAPTA, a strong Ca2+-specific chelator. Change in 
the fluorescence intensity of the donor (cTnI[S151CIAEDANS] or 
cTnI[S167CIAEDANS]) was recorded within 0.3 s. Up to 20 traces 
were obtained for each set of samples, and the average trace was 
fitted to an exponential function to determine the rate constant 
of the conformational change induced by the dissociation of Ca2+ 
from cTnC.
Cosedimentation of Tpm1.1 with F-actin
Prior to each cosedimentation experiment, Tpm1.1 was reduced by 
adding 2 mM DTT, heating for 5 min at 56°C, and aggregates were 
removed by centrifuging for 30 min at 65,000 rpm (Beckman Coul-
ter TLA-120.1 rotor) and 20°C. Cosedimentation assays to quantify 
the affinity of Tpm1.1 (WT or R21H) to F-actin were conducted ac-
cording to a recently published protocol (Colpan et al., 2017) with 
minor changes: 0–3 µM Tpm1.1 (WT or R21H) was used, and the 
F-actin/Tpm1.1 mixture was incubated for 10 min at room tempera-
ture before centrifugation. The data were fitted to both the Hill 
equation (Barua et al., 2011) using SigmaPlot 12.5 and the McGhee–
von Hippel equation (McGhee and von Hippel, 1974), corrected in 
Leinweber et al. (1999), using Prism 7.0 (GraphPad Software, La 
Jolla, CA). Fitting the data to the Hill equation yielded Kapp, which is 











where f is the fraction maximal Tpm1.1 binding to actin or the nor-
malized Tpm1.1/actin band density ratio, a is the maximal bound 
Tpm1.1, c is the free-Tpm1.1 concentration, and n is the Hill coeffi-
cient. Analysis using the McGhee–von Hippel model determined 
Ko, which is the binding constant between Tpm1.1 and an isolated 
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where R n v v n v1 1 4 1
2( )( ) ( )= − + × + × ω × × − × , v is the number 
of moles of bound Tpm1.1 per mole of actin, L is the free-Tpm1.1 
concentration, n the stoichiometry of actin to bound Tpm1.1 
(hence, n = 7), and ω is the increase in Tpm1.1s affinity for a con-
tiguous binding site (an end-to-end contact with an adjacent 
molecule).
ATPase assays
Rates of ATP hydrolysis were measured by the time course of libera-
tion of 32Pi from [γ-32P]ATP on addition of myosin S1 (Chalovich and 
Eisenberg, 1982). The total reaction volume was 0.4 ml, and 0.1 ml 
aliquots of the reaction mixture were analyzed at 4, 8, and 12 min. 
All reactions were linear over that period and the initial rate was 
determined by a linear least-squares fit of the data. Measurements 
were taken at 25°C with 0.1 µM skeletal myosin S1, 10 µM F-actin, 
2.9 µM Tpm (WT or mutated), and 2.9 µM human cTn. The assay 
solution contained 1 mM ATP, 3 mM MgCl2, 34 mM NaCl, 10 mM 
MOPS, pH 7.0, and 1 mM DTT, with 2 mM EGTA or 0.2 mM CaCl2.
Fluorescence measurements of pointed-end polymerization
The rate of actin polymerization was measured as the change in 
pyrene-labeled actin fluorescence using a PTI Quantmaster Model 
QM-40 Spectrofluorometer (HORIBA Scientific, Edison, NJ) (excita-
tion at 366 nm, emission at 387 nm, 2-nm slit width) according to 
Kostyukova and Hitchcock-DeGregori (2004). To measure the inhi-
bition rates of actin polymerization at the pointed ends by Tmod1 
or Lmod1-514, actin seeds (short actin filaments whose barbed ends 
are capped by gelsolin) were prepared by polymerizing 3 µM G-
actin in the presence of 30 nM gelsolin at room temperature for at 
least 1 h. Next, saturating concentrations of Tpm1.1 (1.25 µM for 
WT or 2 µM for R21H) was added to the seeds and incubated for 
1–2 min before 0–50 nM Tmod1 or 0–40 nM Lmod21-514 was added 
to the Tpm1.1-saturated actin seeds. The seeds were diluted five 
times with 1 µM G-actin and 0.1 µM pyrene actin in 2 mM Tris–HCl, 
pH 8.0, 25 mM imidazole, 100 mM KCl, 2 mM MgCl2, 1 mM EGTA, 
0.2 mM CaCl2, 0.01% NaN3, 0.5 mM DTT, and 0.2 mM ATP. The 
data were fitted to an exponential growth to maximum equation 
using SigmaPlot 12.5. The initial rates (R) of polymerization were 
calculated as the first derivatives of the exponential curves at time 
0. Rexp/Rcontrol was calculated as the normalized inhibition of 
pointed-end polymerization by Tmod1 or Lmod21-514, where Rcontrol 
is the rate of pointed-end actin polymerization without any Tpm1.1, 
Tmod1, or Lmod21-514.
Isolation, transduction, and immunofluorescence microscopy 
of neonatal cardiomyocytes
Rat neonatal cardiomyocytes were isolated and plated on matrigel 
thin-coated (BD Biosciences, Franklin Lakes, NJ), 12-mm glass cov-
erslips placed in culture dishes as previously described (Pappas 
et al., 2015). One day after plating, cells were transduced with 20 
multiplicity of infection (MOI) of mCherry-tagged rat Tpm1.1, 
Tpm1.1[K15N], or Tpm1.1[R21H] adenovirus, which were generated 
as previously described (Pappas et al., 2015). The mCherry tag is 
located at the N-terminus of Tpm1.1. At 20 MOI, all cells express 
the tagged proteins.
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Four days after transduction, cells were washed with phosphate-
buffered saline (PBS) and incubated in relaxing buffer (150 mM KCl, 
5 mM MgCl2, 10 mM 3-(N-morpholino)propanesulfonic acid, pH 7.4, 
1 mM EGTA, and 4 mM ATP) for 15 min and fixed with 2% (wt/vol) 
paraformaldehyde in relaxing buffer for 15 min. Cells were then per-
meabilized in 0.2% Triton X-100/PBS for 20 min at room tempera-
ture, blocked with 2% bovine serum albumin (BSA) plus 1% normal 
donkey serum/PBS for 1 h at room temperature, and incubated 1–4 
h at room temperature with primary antibodies/PBS, which included 
mouse monoclonal anti-α-actinin (1:200) (EA-53; Sigma-Aldrich, St. 
Louis, MO), rabbit polyclonal anti-Tmod1 (2 µg/ml), and rabbit poly-
clonal anti-Lmod2 (1 µg/ml) (E-13; Santa Cruz Biotechnology, Dallas, 
TX). Cells were then washed with PBS for 20 min and incubated for 
1.5 h at room temperature with secondary antibodies/PBS, which 
included Alexa Fluor 405-conjugated goat anti-mouse immuno-
globulin G (IgG) (1:200) (Thermo Fisher Scientific) and Alexa Fluor 
647-conjugated donkey anti-rabbit IgG (1:600) (Jackson Immuno-
Research Laboratories, West Grove, PA). Cells were washed with 
PBS for 20 min then mounted onto slides with Aqua Poly/Mount 
(Polysciences, Warrington, PA) or ProLong Diamond Antifade Moun-
tant (Thermo Fisher Scientific). Images were captured using a Nikon 
Eclipse Ti microscope with a 100 × NA 1.5 objective, and a digital 
complementary metal oxide semiconductor (CMOS) camera (ORCA-
flash4.0; Hamamatsu Photonics, Shizuoka Prefecture, Japan). Im-
ages were deconvolved using NIS offline deconvolution software 
(Nikon Corporation, Tokyo, Japan) and processed using Photoshop 
CC (Adobe, San Jose, CA). Cells were considered to have thin- 
filament pointed-end assembly of Lmod2/Tmod1, if a clear striation 
was visible in the majority of sarcomeres within the cell.
Immunoblots
To determine the amount of assembled Tpm, cell lysate collected 
from the same culture dishes as those used for immunofluorescence 
microscopy (after coverslips were removed) was fractionated. Briefly, 
cells were rinsed twice with ice-cold PBS, and then the cytosol ex-
tracted in a Triton X-100–containing cytoskeleton stabilization buffer 
(CSK: 10 mM PIPES, pH 6.8, 100 mM KCl, 300 mM sucrose, 2.5 mM 
MgCl2, 1% Triton X-100 plus protease inhibitors) for 5 min on ice 
while rocking. After two 5-min washes on ice with CSK buffer without 
Triton X-100, the cells were quickly rinsed twice with PBS. The cells 
were then collected in 2x Laemmli buffer with a cell scraper, briefly 
sonicated and incubated at 100°C for 10 min. Lysate was resolved 
on 10% SDS gels and transferred to a nitrocellulose membrane (0.2 
µm pore size; Amersham Protran, GE Healthcare, Little Chalfont, 
United Kingdom). Following transfer, the membrane was blocked 
with 5% (wt/vol) nonfat dried milk/TBS for 1 h at room temperature 
and then incubated with primary antibodies in 1% BSA (wt/vol)/Tris-
buffered saline with 0.1% Tween20 (TBST) overnight at 4°C. Primary 
antibodies included mouse monoclonal anti-Tpm (1:2000) (TM311; 
T2780; Sigma-Aldrich) and a goat polyclonal anti-α-actinin (0.4 µg/
ml) (N19; sc-7453, Santa Cruz Biotechnology). The membranes were 
then washed five times, each for 5 min in TBST and incubated with 
fluorescently labeled anti-rabbit or anti-goat IgG (1:40,000) (Jackson 
ImmunoResearch) diluted in 5% milk/TBST for 1 h at room tempera-
ture. Blots were imaged and analyzed using a LI-COR Odyssey CLx 
imaging system (LI-COR Biosciences, Lincoln, NE).
Transmission electron microscopy imaging
G-actin (4 µM) was incubated in 0.4 mM ATP, 2 mM Tris, pH 7.5, 
0.2 mM CaCl2, 0.01% NaN3, and 0.5 mM DTT for 10 min on ice. 
Polymerization buffer (20X) was added to G-actin to reach a final 
concentration of 1X (100 mM KCl, 25 mM imidazole, pH 8.0, 2 mM 
MgCl2, 1 mM EGTA, and 0.1 mM ATP), and actin was polymerized 
for 30 min at room temperature. F-actin was kept at 4°C for several 
hours during TEM imaging. From the same batch of prepared F-
actin, all TEM samples (including the actin-only control) were pre-
pared. Wild-type Tpm1.1 (1.25 µM) or 2 µM Tpm1.1[R21H] was 
added to F-actin and the mixture was incubated at 4°C for 10 min. 
Lmod2 (0.9 µM) was added to F-actin in the absence or presence of 
Tpm1.1 and incubated at room temperature for 10 min.
To visualize complexes of F-actin with Lmod2 and with or without 
bound Tpm1.1, aliquots (7 µl) were applied to glow-discharged 
carbon-coated grids (Electron Microscopy Sciences, Hatfield, PA) 
and stained with 2% uranyl acetate. The grids were examined in a 
JEOL 1200 EXII transmission electron microscope (JEOL USA, Pea-
body, MA) under regular dose conditions at an accelerating voltage 
of 70 keV.
Pellet samples from cosedimentation assays were run on 10% 
polyacrylamide SDS gels. The gels were scanned using ChemiDoc 
XRS (Bio-Rad, Hercules, CA) and quantified using the National 
Institutes of Health ImageJ software.
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